RxDoctor Payments Data

Opeyemi Oladele, MD

Nephrology · Victorville, CANPI 1801154380

Payments from drug & device makers

$1,562in general payments, 2019–2025

Across 63 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Welch Allyn$206
  • AstraZeneca$153
  • GSK$130
  • Otsuka America Pharmaceutical, Inc.$122
  • Baxter Healthcare$121
  • Amgen$113
  • plus $717 from 16 others

What the payments were for

  • Food & beverage$1,22278%
  • Education$141%
  • Other$32721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,562 in reported general payments places this provider in the 50th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$216,141
Medicare patients
400
Services billed
1,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$254,641
XphozahTenapanor Hcl65$185,309
JanuviaSitagliptin Phosphate124$80,328
JardianceEmpagliflozin96$58,929
AuryxiaFerric Citrate24$58,913
LokelmaSodium Zirconium Cyclosilicate45$36,769
VelphoroSucroferric Oxyhydroxide18$36,282
KerendiaFinerenone47$36,171
FarxigaDapagliflozin Propanediol41$27,957
Sevelamer Hcl15$26,931
VeltassaPatiromer Calcium Sorbitex18$16,642
Sevelamer Carbonate71$12,375
InvokanaCanagliflozin13$8,745
DapagliflozinDapagliflozin Propanediol18$7,478
ClinisolParenteral Amino Acid 15% No.547$6,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$122$254,64113 claims
AstraZenecaLokelma, Farxiga$153$64,72686 claims
Boehringer IngelheimJardiance$16$58,92996 claims
Akebia Therapeutics IncAuryxia$45$58,91324 claims
BayerKerendia$78$36,17147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,341 nephrology providers in California.

Other nephrology in Victorville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →